| Date Filed | Type | Description |
| 10/12/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/06/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Granted 2,788,620 options to buy
@ $0.001, valued at
$2.8k
Granted 1,394,310 options to buy
@ $5.38, valued at
$7.5M
Granted 1,690,014 options to buy
@ $8.877, valued at
$15M
|
|
| 10/06/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.9% stake in Vistagen Therapeutics, Inc. |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/09/2023 |
SC 13G
| COMMODORE CAPITAL LP reports a 19.7% stake in Vistagen Therapeutics, Inc. |
| 08/09/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Vistagen Therapeutics, Inc.|
Txns:
| Bought 775,756 shares
@ $23.153, valued at
$18M
|
|
| 08/09/2023 |
3
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 3 on Vistagen Therapeutics, Inc. |
| 04/27/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/28/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/27/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Bought 622 shares
@ $22.072, valued at
$13.7k
Acquired 729,891 shares
@ $0 |
|
| 02/23/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on IMARA Inc.|
Txns:
| Bought 8,194 shares
@ $5.249, valued at
$43k
Bought 23,565 shares
@ $5.113, valued at
$120.5k
|
|
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.5% stake in Imara Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 1.7% stake in Karyopharm Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 0% stake in VistaGen Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 4.2% stake in BELLUS Health Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 6.8% stake in CymaBay Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 6.3% stake in Immunic, Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 9.9% stake in Celcuity Inc. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 5.9% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 7% stake in Cogent Biosciences, Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/13/2023 |
SC 13G
| COMMODORE CAPITAL LP reports a 5% stake in Cabaletta Bio, Inc. |
| 11/16/2022 |
SC 13G/A
| COMMODORE CAPITAL LP reports a 0% stake in Satsuma Pharmaceuticals, Inc. |
| 11/16/2022 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Sold 3,250,000 shares
@ $0.706, valued at
$2.3M
|
|
| 10/24/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/21/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/19/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/09/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/14/2022 |
SC 13G
| COMMODORE CAPITAL LP reports a 5.1% stake in VistaGen Therapeutics, Inc. |
|